Search Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapySolid TumorsProtocol groupradiotherapyUrologic OncologyDiseaseBladder CancerRenal Pelvic CarcinomaSubgroupFGFR2/3 FusionFGFR3 MutationHigh risknon-muscle invasivePD-L1 with CPS from 10PD-L1+unfitUrothelial Carcinoma of the Upper Urinary TractICD10C65C67.-MeSHCarcinoma, Transitional CellUreteral NeoplasmsUrinary Bladder NeoplasmsUrogenital NeoplasmsUrologic NeoplasmsSequenceCheckMate 901: NIVO360/GEMC1000/CISP70, Urinary Bladder Ca (PID2490) -|- NIVO480 Maint. (PID2491)JAVELIN Bladder 100: GEMC1000/CISP70, urinary bladder Ca (PID544) -|- AVEL800, maint. (PID679)JAVELIN Bladder 100: GEMC1000/CRBP5, urinary bladder Ca (PID1502) -|- AVEL800, maint. (PID679)NIAGARA: DURV1500/GEMC1000/CISP70, Bladder Cancer, neoadj., C1-4 (PID2718) or DURV1500/CISP35/GEMC1000, Bladder Cancer, neoadj., C1-4 (PID2720) -|- DURV1500, adj., C5-12 (PID2719)TITAN-TCC: NIVO240, Bladder Cancer, C1-4 (PID2694) -|- NIVO1/IPIL3, C5-8 (PID2695) -|- NIVO (PID1007)ChemotherapyChemo-substanceAtezolizumabAvelumabCapecitabineCarboplatinCisplatinDoxorubicinDurvalumabEnfortumab VedotinErdafitinibFluorouracilGemcitabineIpilimumabMethotrexateMitomycinNab-paclitaxelNivolumabPaclitaxelPembrolizumabPemetrexedSacituzumab GovitecanVinblastineVinfluninChemo-substanceAtezolizumabAvelumabCapecitabineCarboplatinCisplatinDoxorubicinDurvalumabEnfortumab VedotinErdafitinibFluorouracilGemcitabineIpilimumabMethotrexateMitomycinNab-paclitaxelNivolumabPaclitaxelPembrolizumabPemetrexedSacituzumab GovitecanVinblastineVinfluninChemo-substanceAtezolizumabAvelumabCapecitabineCarboplatinCisplatinDoxorubicinDurvalumabEnfortumab VedotinErdafitinibFluorouracilGemcitabineIpilimumabMethotrexateMitomycinNab-paclitaxelNivolumabPaclitaxelPembrolizumabPemetrexedSacituzumab GovitecanVinblastineVinfluninChemo-substanceAtezolizumabAvelumabCapecitabineCarboplatinCisplatinDoxorubicinDurvalumabEnfortumab VedotinErdafitinibFluorouracilGemcitabineIpilimumabMethotrexateMitomycinNab-paclitaxelNivolumabPaclitaxelPembrolizumabPemetrexedSacituzumab GovitecanVinblastineVinfluninNo. Substances1234 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionCimetidineCyanocobalaminDexamethasoneDimetindenFolic acidFolinic acidFosaprepitantGranisetronMagnesiumMagnesium sulfateNaCl 0.9%ParacetamolPegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionCimetidineCyanocobalaminDexamethasoneDimetindenFolic acidFolinic acidFosaprepitantGranisetronMagnesiumMagnesium sulfateNaCl 0.9%ParacetamolPegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionCimetidineCyanocobalaminDexamethasoneDimetindenFolic acidFolinic acidFosaprepitantGranisetronMagnesiumMagnesium sulfateNaCl 0.9%ParacetamolPegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionCimetidineCyanocobalaminDexamethasoneDimetindenFolic acidFolinic acidFosaprepitantGranisetronMagnesiumMagnesium sulfateNaCl 0.9%ParacetamolPegfilgrastimPotassium chlorideNo. Substances12345678910Protocol classificationTherapy classificationalternativecurrent standardIntensityDose intensifiedStandard doseTherapy indicationFirst lineRelapse therapySecond lineseveral possibleTherapy phaseMaintenanceneoadjuvantseveral possibleTherapy intentioncurativepalliativeRisksAcute Kidney InjuryAdrenal InsufficiencyAlopeciaAnemia Hb below 8g/dlAnemia Hb below 10g/dlArthalgiaAstheniaBleedingCardiotoxicityColitisConstipationDiabetic KetoacidosisDiarrheaDyspneaEdemaEmetogenicityEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)FatigueFebrile NeutropeniaGastrointestinal ToxicityHand-Foot SyndromeHematuriaHepatotoxicityHyperglycemiaHyperphosphatemiaHypertensionHyperthyroidismHypocalcemiaHypokalemiaHypomagnesemiaHyponatremiaHypophosphatemiaHypotensionHypothyroidismIncrease Alkaline PhosphataseIncrease AminotransferasesIncrease in lipaseInfectionsInfusion ReactionLeukopeniaLymphopeniaMucositisMuscle WeaknessMyocarditisMyositisNauseaNephrotoxicityNeuropathyNeutropeniaOral MucositisPainPneumonitisPruritusPyrexiaRashRenal FailureRenal failure!SepsisThrombocytopenia below 50 000/µlThromboembolic EventUpper Respiratory Tract InfectionVisual DisturbancesVomiting only studiesPublicationAuthorAlbers PBajorin DFBalar ABellmunt JBirtle AChoudhury AColeman JACoppin CMDash Ade Haar-Holleman ADe Santis MGiannatempo PGrimm MOGrivas PGrossman HBIacovelli RRInternational Collaboration of TrialistsJames NJoly FKo YJLoriot YMassard CNecchi A Pfister CPowles TRosenberg JRosenberg JESharama PSternberg CNSweeney CJTagawa STvan der Heijden MS von der Maase HDiseaseHarnblasen-Ca, operabel bis T4aHarnblasenkarzinom, muskelinvasiv, nicht metastasiert, ECOG 0-2Harnblasenkarzinom, muskelinvasiv, Stadium cT2-T4a, cN0/1 und cM0Harnblasenkarzinom, nicht-muskelinvasiv, high-risk (T1 oder high-grade Ta), nach TUR-B, nach Therapie mit BCG und fehlendem Ansprechen, ECOG 0-2inoperables oder metastasiertes Harnblasenkarzinom, ECOG 0-1lokal fortgeschrittenes oder metastasierendes Harnblasenkarzinom, nach 1-2 Vortherapien, ECOG 0-1lokal fortgeschrittenes oder metastasierendes Harnblasenkarzinom, Progress nach Platin, ECOG 0-2Lokal fortgeschrittenes oder metastasiertes Harnblasen-Ca, Erstlinie, ECOG 0-1Lokal fortgeschrittenes oder metastasiertes Harnblasen-Ca, Progress nach platinbasierter Chemotherapie, ECOG 0-1Lokal fortgeschrittenes oder metastasiertes Harnblasenkarzinom, mind. 1 Vortherapie, FGFR3 Mutation oder FGFR2/3 Fusion, ECOG 0-2Lokal fortgeschrittenes oder metastasiertes Harnblasenkarzinom, mindestens 1 Vortherapie (neoadjuvant, adjuvant, oder palliativ), ECOG 0-2Lokal fortgeschrittenes oder metastasiertes Harnblasenkarzinom, Zweitlinientherapie, ECOG 0-1lokal fortgeschrittenes oder metastasiertes Harnblasenkarzinom nach Platintherapie, ECOG 0-1lokal fortgeschrittenes oder metastasiertes Urothelkarzinom, ohne Vorbehandlung, ECOG 0-1Lokal fortgeschrittenes oder metastasiertes Urothelkarzinom nach platinhaltiger Therapie und Therapie mit Anti-PD-1/L1-Inhibitoren, ECOG 0-1lokal fortgeschrittenes und nicht resezierbares oder metastasiertes Harnblasenkarzinom, ungeeignet für eine Cisplatin-Therapie, ECOG 0-2Metastasiertes Harnblasenkarzinom, Progress nach platinhaltiger oder Checkpoint-Inhibitor-TherapieMetastasiertes oder lokal fortgeschrittenes nicht operables Harnblasenkarzinom, cisplatin-ungeeignet, PD-L1 positivMetastasiertes oder lokal fortgeschrittenes nicht operables Harnblasenkarzinom, ECOG 0-1metastasiertes oder nicht-resektables lokal fortgeschrittenes Urothelkarzinom, Zweitlinie nach Platin, ECOG 0-1muskelinvasives Harnblasen-Ca, cT2 G3, cT3, oder cT4a und cN0/X, cM0muskelinvasives Harnblasen-Ca, cT2, cT3, oder cT4a N0, ECOG 0-1Muskelinvasives Harnblasenkarzinom, cT2-cT4b, cN0-N3, cM0 Muskelinvasives Urothelkarzinom, adjuvantMuskelinvasives Urothelkarzinom des oberen Harntraktes, entweder pT2–T4 pN0–N3 M0 oder pT1-4 pN1–3 M0Muskelinvasives Urothelkarzinom des oberen Harntraktes, high-grade, cT2-T4a cN0/X cM0nicht operabeles, lokal fortgeschrittenes oder metastasiertes Urothelkarzinom, Cisplatin- ungeeignet, Erstlinie, ECOG 0-2TCC, muskelinvasives, fortgeschrittenes Harnblasen-Ca, neoadjuvant, ECOG 0-1TCC des Urothels, fortgeschr. oder metastasiert, ErstlinieTCC des Urothels, fortgeschr. oder metastasiert, Progress nach platin-haltiger Erstlinie, ECOG 0-1TCC des Urothels, fortgeschritten oder metastasiert, Erstlinie, ECOG 0-2Urothel-Ca, Progress oder Rezidiv nach/unter Cisplatin Erstlinientherapie, Karnofsky Status > 60%Urothelkarzinom, cT2-4a cN0-2/x cM0/xUrothelkarzinom, fortgeschritten oder metastasiert, Erstlinie, ECOG 0-1Urothelkarzinom, metastasiert oder lokal fortgeschritten, Progress nach platin-basierter Therapie, max. drei VortherapienUrothelkarzinom inoperabel oder metastasiert, ECOG 2 und/oder GFR zwischen 30 und 60 ml/min, ErstlinientherapieUrothelkarzinom T2-3, N0, M0 nach transurethraler ResektionOriginArhus University Hospital, DänemarkBarts Cancer Institute, Queen Mary University of London, NIAGARA trialBarts Cancer Institute Biomedical Research Centre, Queen Mary University of London, LondonCentre Francois Baclesse, Caen, FranceCharles Nicolle University Hospital, Rouen, France, GETUG/AFU V05 VESPER TrialDana-Farber Cancer Institute, BostonDepartment of Medical Oncology, University Hospital de Mar, SpanienDepartment of Urology, Düsseldorf UniversityDivision of Cancer Medicine, The University of Texas, M.D. Anderson Cancer Center, Houston, SWOG 8710Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, PEANUT studyFred Hutchinson Cancer Center, University of Washington, Seattle, WA, TROPHY-U-01 trialFront the British Columbia Cancer Agency Vancouver Cancer Centre, CanadaGenitourinary Cancers Program, Perlmutter Cancer Center. New York University Langone Medical Center, IMvigor210 Study GroupGenitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, IMvigor210Hoosier Oncology Group, Indianapolis, Indiana, USAInstitut Gustave Roussy Cancer Centre, Villejuif, FranceJena University Hospital, Friedrich-Schiller University Jena, Jena, Germany, TITAN-TCC trialKaiser Franz Josef Hospital, Vienna, Austria, EORTC Study 30986MD Anderson Cancer Center, University of Texas, Houston, USA, CheckMate 275Medical Research Council Clinical Trials Unit, London, United Kingdom, BA06 30894 TrialMemorial Sloan Kettering Cancer Center, New York, CheckMate 274 StudyMemorial Sloan Kettering Cancer Center, New York, NYMemorial Sloan Kettering Cancer Center, New York, USAMemorial Sloan Kettering Cancer Center, New York, USA, EV-201 trialNetherlands Cancer Institute, Amsterdam, CheckMate 901 TrialOncologia Medica, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, ItalyPerlmutter Cancer Center, NYU Langone Medical Center, New YorkQueen Mary University of London, St. Bartholomew's Hospital, London, JAVELIN Bladder 100Sunnybrook Odette Cancer Centre, Toronto, CanadaThe Christie NHS Foundation Trust, Wilmslow Rd, Manchester, United KingdomUniversitair Ziekenhuis Brussel, Brussels, Belgium, BlaZIB study Universite Paris-Sud, Universite Paris-Saclay, Villejuif, France, BLC2001 Study GroupUniversity of Birmingham, School of Cancer Sciences, UKUniversity of Manchester, Manchester, UK, POUT trialVall d’Hebron University Hospital and University Hospital del Mar, BarcelonaVincenzo Pansadoro Foundatoin, Rome, ItalienVita-Salute San Raffaele University, IRCCS San Raffaele Hospital, Milan, Italy, KEYNOTE-057 trialWeill Cornell Medicine, New York, NY, TROPHY-U-01Protocols in Revision 50 protocols foundProtocols under revision.Atezolizumab 1200, Bladder Cancer, first line (PID1034 V1.1)Atezolizumab 1200, Bladder Cancer, Second Line (PID1026 V1.0)Atezolizumab 1680, Bladder Cancer, First Line (PID1659 V1.0)Atezolizumab 1680, Bladder Cancer, Second Line (PID1661 V1.0)Atezolizumab 840, Bladder Cancer, First Line (PID1658 V1.0)Atezolizumab 840, Bladder Cancer, Second Line (PID1660 V1.0)Avelumab 800, Bladder Cancer (PID2179 V1.0)Avelumab 800, Bladder Cancer, Maintenance (PID679 V1.1)Capecitabine 825 / Mitomycin 12 / Radiation, Bladder Cancer (PID2505 V1.0)Cisplatin 100 / Radiation, Bladder Cancer (PID1668 V1.1)Durvalumab 10, Bladder Cancer (PID471 V1.0)Durvalumab 1500 / Cisplatin 35 / Gemcitabine 1000, Bladder Cancer, neoadjuvant, cycle 1-4 (PID2720 V1.0)Durvalumab 1500 / Cisplatin 70 / Gemcitabine 1000, Bladder Cancer, neoadjuvant, cycle 1-4 (PID2718 V1.0)Durvalumab 1500 / Gemcitabine 1000 / Cisplatin 70 - Durvalumab 1500, Bladder Cancer, adjuvant, cycle 5-12 (PID2719 V1.0)Enfortumab Vedotin 1.25 / Pembrolizumab 200, Bladder Cancer (PID2366 V1.1)Enfortumab Vedotin 1.25, Bladder Cancer (PID1733 V1.1)Erdafitinib 8, urinary Bladder Cancer (PID2001 V1.0)Fluorouracil 500 / Mitomycin 12 / Radiation, Bladder Cancer (PID949 V1.0)Gemcitabine 100 / Radiation, Bladder Cancer (PID2213 V1.0)Gemcitabine 1000 / Carboplatin 5, Bladder Cancer (PID1502 V1.0)Gemcitabine 1000 / Carboplatin 5, Bladder Cancer, adjuvant (PID1491 V1.1)Gemcitabine 1000 / Cisplatin 35, Bladder Cancer, Neoadjuvant (PID2246 V1.0)Gemcitabine 1000 / Cisplatin 35, Bladder Cancer, Neoadjuvant (PID1499 V1.1)Gemcitabine 1000 / Cisplatin 70, Bladder Cancer (PID544 V1.1)Gemcitabine 1000 / Cisplatin 70, Bladder Cancer Adjuvant (PID1490 V1.0)Gemcitabine 1000 / Cisplatin 70, Bladder Cancer, Neoadjuvant (PID562 V1.1)Gemcitabine 1000 / Paclitaxel 175, Bladder Cancer, Second Line (PID1300 V1.1)Methotrexate 30 / Vinblastine 3 / Doxorubicin 30 / Cisplatin 70, dose-dense, Bladder Cancer (PID545 V1.2)Methotrexate 30 / Vinblastine 3 / Doxorubicin 30 / Cisplatin 70, Urinary Bladder Carcinoma, neoadjuvant (PID663 V1.2)Methotrexate 30 / Vinblastine 3 / Doxorubicin 30 / Cisplatin 70, Urinary Bladder Carcinoma, neoadjuvant (PID1991 V1.1)Methotrexate 30 / Vinblastine 4 / Cisplatin 100, Urinary Bladder Carcinoma, neoadjuvant (PID1992 V1.0)Nab-Paclitaxel 260, Bladder Cancer (PID1528 V1.0)Nivolumab 1 / Ipilimumab 3, Bladder Cancer, Cycle 5-8 (PID2695 V1.0)Nivolumab 240, Bladder Cancer (PID1007 V2.0)Nivolumab 240, Bladder Cancer, Adjuvant (PID1801 V1.0)Nivolumab 240, Bladder Cancer, Cycle 1-4 (PID2694 V1.0)Nivolumab 360 / Gemcitabine 1000 / Cisplatin 70 - Nivolumab 480 Maintenance, Bladder Cancer (PID2491 V1.0)Nivolumab 360 / Gemcitabine 1000 / Cisplatin 70, Bladder Cancer (PID2490 V1.0)Paclitaxel 80 / Gemcitabine 1000 / Cisplatin 70, Bladder Cancer (PID1359 V1.3)Paclitaxel 80, Bladder Cancer (PID1527 V1.0)Pembrolizumab 200 / Nab-Paclitaxel 125, Bladder Cancer (PID1767 V1.0)Pembrolizumab 200 / Sacituzumab Govitecan 10, Bladder Cancer (PID2562 V1.0)Pembrolizumab 200, Bladder Cancer, adjuvant (PID2693 V1.0)Pembrolizumab 200, Bladder Cancer, First Line (PID1158 V1.0)Pembrolizumab 200, Bladder Cancer, Second Line (PID99 V1.0)Pembrolizumab 400, Bladder Cancer, First Line (PID1262 V1.0)Pembrolizumab 400, Bladder Cancer, Second Line (PID1263 V1.0)Pemetrexed 500, Bladder Cancer (PID1526 V1.0)Sacituzumab Govitecan 10, Bladder Cancer (PID2000 V1.1)Vinflunin 320, Bladder Cancer (PID563 V1.0)
